Simvastatin inhibited the activation of RhoA and RAS/ERK systems and then inhibited cardiac hypertrophy, but not myocardial fibrosis, in SHR+SAD without affecting BP variability. The gene discussed is RHOA; the disease is cardiac hypertrophy.